BioCentury | Jan 24, 2011
Finance

Less VC, more SBIR

...$10 million in grants, with another $4 million in pending awards, since spinning off from Sunol Molecular Corp....
BioCentury | Feb 18, 2008
Company News

Altor BioScience, Genentech deal

...was spun out of Sunol Molecular Corp. , which discovered and performed early development of the compounds. Sunol...
BioCentury | Sep 4, 2006
Company News

Accera management update

...Broomfield, Colo. Business: Neurology Hired: Dean Taylor as VP of business development, formerly COO of Sunol Molecular Corp. WIR...
BioCentury | Apr 4, 2005
Company News

Tanox, Sunol deal

...TNOX agreed to acquire Sunol's tissue factor antagonist program to treat inflammatory diseases and cancer for...
...cancer for stock and cash. TNOX will issue 800,000 shares and pay $6 million to Sunol...
...rights to technologies and IP for protein and antibody expression. Tanox Inc. (TNOX), Houston, Texas Sunol Molecular Corp....
BioCentury | Mar 29, 2005
Company News

Tanox, Sunol tissue factor deal

...TNOX agreed to acquire for stock and cash Sunol Molecular's tissue factor antagonist program to treat...
...treat inflammatory diseases and cancer. TNOX will issue 800,000 shares and pay $6 million to Sunol...
BioCentury | Nov 1, 2004
Strategy

Biomarker deals

...Biomarker deals Caprion Partner Deal description Date Sunol Molecular Caprion received rights to develop antibodies in...
BioCentury | Nov 1, 2004
Strategy

Biomarkers missing the mark(et)

...bring them to market for more targeted patient populations, Segal said. In a deal with Sunol Molecular Corp....
BioCentury | Jun 14, 2004
Strategy

Caprion HUStles to the clinic

...of product development capabilities but also of a product discovery platform. Last week's deal with Sunol Molecular Corp....
...lung, colon and prostate cancers. Now, Caprion has licensed exclusive rights to two antibodies from Sunol...
...said. In the second leg of the deal, Caprion (Montreal, Quebec) obtained non-exclusive rights to Sunol's...
BioCentury | Jun 14, 2004
Company News

Caprion, Sunol deal

...Caprion acquired exclusive rights from Sunol to therapeutic antibodies in Phase I development to treat hemolytic...
...hemolytic uremic syndrome (HUS) resulting from E. coli infection. Caprion also acquired non-exclusive rights to Sunol's...
...Initially, Caprion will develop antibodies to treat solid tumors. Caprion Pharmaceuticals Inc. , Montreal, Quebec Sunol Molecular Corp....
BioCentury | Jan 10, 2000
Emerging Company Profile

InterCell GmbH

...by Max Birnstiel, Michael Buschle, Alexander von Gabain, Aaron Hirsh and Walter Schmidt Corporate partners: Sunol Molecular Corp....
Items per page:
1 - 10 of 13
BioCentury | Jan 24, 2011
Finance

Less VC, more SBIR

...$10 million in grants, with another $4 million in pending awards, since spinning off from Sunol Molecular Corp....
BioCentury | Feb 18, 2008
Company News

Altor BioScience, Genentech deal

...was spun out of Sunol Molecular Corp. , which discovered and performed early development of the compounds. Sunol...
BioCentury | Sep 4, 2006
Company News

Accera management update

...Broomfield, Colo. Business: Neurology Hired: Dean Taylor as VP of business development, formerly COO of Sunol Molecular Corp. WIR...
BioCentury | Apr 4, 2005
Company News

Tanox, Sunol deal

...TNOX agreed to acquire Sunol's tissue factor antagonist program to treat inflammatory diseases and cancer for...
...cancer for stock and cash. TNOX will issue 800,000 shares and pay $6 million to Sunol...
...rights to technologies and IP for protein and antibody expression. Tanox Inc. (TNOX), Houston, Texas Sunol Molecular Corp....
BioCentury | Mar 29, 2005
Company News

Tanox, Sunol tissue factor deal

...TNOX agreed to acquire for stock and cash Sunol Molecular's tissue factor antagonist program to treat...
...treat inflammatory diseases and cancer. TNOX will issue 800,000 shares and pay $6 million to Sunol...
BioCentury | Nov 1, 2004
Strategy

Biomarker deals

...Biomarker deals Caprion Partner Deal description Date Sunol Molecular Caprion received rights to develop antibodies in...
BioCentury | Nov 1, 2004
Strategy

Biomarkers missing the mark(et)

...bring them to market for more targeted patient populations, Segal said. In a deal with Sunol Molecular Corp....
BioCentury | Jun 14, 2004
Strategy

Caprion HUStles to the clinic

...of product development capabilities but also of a product discovery platform. Last week's deal with Sunol Molecular Corp....
...lung, colon and prostate cancers. Now, Caprion has licensed exclusive rights to two antibodies from Sunol...
...said. In the second leg of the deal, Caprion (Montreal, Quebec) obtained non-exclusive rights to Sunol's...
BioCentury | Jun 14, 2004
Company News

Caprion, Sunol deal

...Caprion acquired exclusive rights from Sunol to therapeutic antibodies in Phase I development to treat hemolytic...
...hemolytic uremic syndrome (HUS) resulting from E. coli infection. Caprion also acquired non-exclusive rights to Sunol's...
...Initially, Caprion will develop antibodies to treat solid tumors. Caprion Pharmaceuticals Inc. , Montreal, Quebec Sunol Molecular Corp....
BioCentury | Jan 10, 2000
Emerging Company Profile

InterCell GmbH

...by Max Birnstiel, Michael Buschle, Alexander von Gabain, Aaron Hirsh and Walter Schmidt Corporate partners: Sunol Molecular Corp....
Items per page:
1 - 10 of 13